Funding for this research was provided by:
Gilead Sciences Hellas (Asklepios 2015)
Received: 21 October 2021
Accepted: 19 January 2022
First Online: 29 January 2022
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the local institution (protocol code 2601, date of approval 23-3-2016). Informed consent was obtained from all subjects.
: Not applicable.
: Andreas Laras, Margarita Papatheodoridi, Eleni Panopoulou, Stephanos J Hadziyannis and Emilia Hadziyannis: Nothing to declare. George V Papatheodoridis: advisor/lecturer for Abbvie, Dicerna, Elpen, Gilead, GlaxoSmithKline, Ipsen, Janssen, Merck Sharp & Dohme, Novo Nordisk, Roche, Spring Bank, Takeda; research grants from Abbvie, Gilead.